{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:26:09Z","timestamp":1770279969917,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016838","name":"Berlin Mathematical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016838","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejca.2018.10.015","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T19:57:36Z","timestamp":1543953456000},"page":"181-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"special_numbering":"C","title":["Intense dose-dense epirubicin, paclitaxel, cyclophosphamide\u00a0versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto\u2014GBG 84): A randomised phase III trial"],"prefix":"10.1016","volume":"106","author":[{"given":"Andreas","family":"Schneeweiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"M\u00f6bus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Hanusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Denkert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"L\u00fcbbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Huober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Klare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherko","family":"K\u00fcmmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6531-755X","authenticated-orcid":false,"given":"Karin","family":"Kast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Jackisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Thomalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Ingold-Heppner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens-Uwe","family":"Blohmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdi","family":"Rezai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Frank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knut","family":"Engels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Rhiem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Andreas","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Nekljudova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunter","family":"von Minckwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.10.015_bib1","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1200\/JCO.2005.02.6187","article-title":"Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update","volume":"24","author":"Kaufmann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials","volume":"19","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib3","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1200\/JCO.2004.09.062","article-title":"Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience","volume":"22","author":"Chen","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2018.10.015_bib5","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib6","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib7","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1200\/JCO.2009.24.7643","article-title":"Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study","volume":"28","author":"Moebus","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/annonc\/mdx690","article-title":"Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial","volume":"29","author":"M\u00f6bus","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib9","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2015.60.9271","article-title":"Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer","volume":"33","author":"Sparano","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.ejca.2018.10.015_bib10","doi-asserted-by":"crossref","first-page":"GS1-01","DOI":"10.1158\/1538-7445.SABCS17-GS1-01","volume":"78","author":"Gray","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2018.10.015_bib11","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.10.015_bib12","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups","volume":"29","author":"Untch","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib14","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.10.015_bib16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.520","article-title":"Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC)","volume":"35","author":"Geyer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.ejca.2018.10.015_bib19","first-page":"S2","article-title":"Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive breast cancer (GeparSixto)","volume":"76","author":"von Minckwitz","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2018.10.015_bib20","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","article-title":"Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial","volume":"3","author":"Hahnen","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Pearson","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.ejca.2018.10.015_bib22","unstructured":"National Comprehensive Cancer Network Guidelines. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf [accessed on 10.07.2018]."},{"key":"10.1016\/j.ejca.2018.10.015_bib23","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer","volume":"358","author":"Sparano","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.10.015_bib24","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/S0140-6736(14)62048-1","article-title":"Flourouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomized phase 3 trial","volume":"385","author":"Del Mastro","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2018.10.015_bib25","unstructured":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie. Guidelines of the AGO Breast Committee, https:\/\/www.ago-online.de\/en\/guidelines-mamma\/march-2018\/[accessed on 09.07.2018]."},{"key":"10.1016\/j.ejca.2018.10.015_bib26","author":"e.V. Deutsche Krebsgesellschaft"},{"key":"10.1016\/j.ejca.2018.10.015_bib27","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/annonc\/mdx203","article-title":"German adjuvant intergroup node-positive study (gain): a phase III trial comparing two dose-dense regimens (iddEPC vs. ddEC-PwX) in high-risk early breast cancer patients","volume":"28","author":"M\u00f6bus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib28","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1200\/JCO.2012.48.1275","article-title":"Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial","volume":"31","author":"Swain","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial","volume":"17","author":"Untch","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib30","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2008.20.3133","article-title":"Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer","volume":"27","author":"Untch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib31","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdq709","volume":"22","author":"Untch","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib33","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s12032-011-0002-1","article-title":"Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission","volume":"29","author":"Mark","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib34","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s12032-011-9893-0","article-title":"Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer","volume":"29","author":"Inaba","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.ejca.2018.10.015_bib35","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1200\/JCO.2005.09.423","volume":"23","author":"Levine","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918314564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918314564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:23:03Z","timestamp":1760732583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918314564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":35,"alternative-id":["S0959804918314564"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.10.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intense dose-dense epirubicin, paclitaxel, cyclophosphamide\u00a0versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto\u2014GBG 84): A randomised phase III trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}